Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

•Selpercatinib and pralsetinib both have high extracranial efficacy in RET fusion-positive non-small cell lung cancer (NSCLC). •We present a case of a patient with RET fusion-positive NSCLC who had a durable extracranial response to pralsetinib, but had leptomeningeal progression. She subsequently had both a clinical and radiographic CNS response to selpercatinib. •Future studies should compare the intracranial efficacy with these 2 RET...